COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas

Glioma is the most common malignancy of the central nervous system. Although advances in surgical resection, adjuvant radiotherapy, and chemotherapy have been achieved in the last decades, the prognosis of gliomas is still dismal. COL5A1 is one of the collagen members with minor content but prominen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sujie Gu, Zesheng Peng, Yuxi Wu, Yihao Wang, Deqiang Lei, Xiaobing Jiang, Hongyang Zhao, Peng Fu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	COL5A1 glioma temozolomide resistance tumor-infiltrating immune cells (TIICs) tumor progression bioinformatics analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/0cdfcbe515de420083fb0eb4c747a0da
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0cdfcbe515de420083fb0eb4c747a0da
record_format	dspace
spelling	oai:doaj.org-article:0cdfcbe515de420083fb0eb4c747a0da2021-11-16T05:57:12ZCOL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas2234-943X10.3389/fonc.2021.752694https://doaj.org/article/0cdfcbe515de420083fb0eb4c747a0da2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.752694/fullhttps://doaj.org/toc/2234-943XGlioma is the most common malignancy of the central nervous system. Although advances in surgical resection, adjuvant radiotherapy, and chemotherapy have been achieved in the last decades, the prognosis of gliomas is still dismal. COL5A1 is one of the collagen members with minor content but prominent functions. The present study examined the biological functions, prognostic value, and gene-associated tumor-infiltrating immune cells of COL5A1 through experiments and bioinformatics analysis. We found that the overexpression of COL5A1 was positively correlated with the increasing tumor malignancies and indicated poor prognosis in gliomas. Moreover, downregulation of COL5A1 could inhibit proliferation and migration of glioma cells and enhance their temozolomide sensitivities in vitro. Further bioinformatic analysis revealed that COL5A1 and its co-expressed genes participated in a number of pathways and biological processes involved in glioma progression. Finally, we evaluated the tumor-infiltrating immune cells of gliomas depending on COL5A1 and found that the percentages of the dendritic cells, which were known as the central mediator of tumor microenvironment in gliomas, were positively associated with the expression levels of COL5A1. Taken together, COL5A1 is an important biomarker and potential therapeutic target of gliomas.Sujie GuZesheng PengZesheng PengYuxi WuYihao WangDeqiang LeiXiaobing JiangHongyang ZhaoPeng FuFrontiers Media S.A.articleCOL5A1gliomatemozolomide resistancetumor-infiltrating immune cells (TIICs)tumor progressionbioinformatics analysisNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COL5A1 glioma temozolomide resistance tumor-infiltrating immune cells (TIICs) tumor progression bioinformatics analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	COL5A1 glioma temozolomide resistance tumor-infiltrating immune cells (TIICs) tumor progression bioinformatics analysis Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Sujie Gu Zesheng Peng Zesheng Peng Yuxi Wu Yihao Wang Deqiang Lei Xiaobing Jiang Hongyang Zhao Peng Fu COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas
description	Glioma is the most common malignancy of the central nervous system. Although advances in surgical resection, adjuvant radiotherapy, and chemotherapy have been achieved in the last decades, the prognosis of gliomas is still dismal. COL5A1 is one of the collagen members with minor content but prominent functions. The present study examined the biological functions, prognostic value, and gene-associated tumor-infiltrating immune cells of COL5A1 through experiments and bioinformatics analysis. We found that the overexpression of COL5A1 was positively correlated with the increasing tumor malignancies and indicated poor prognosis in gliomas. Moreover, downregulation of COL5A1 could inhibit proliferation and migration of glioma cells and enhance their temozolomide sensitivities in vitro. Further bioinformatic analysis revealed that COL5A1 and its co-expressed genes participated in a number of pathways and biological processes involved in glioma progression. Finally, we evaluated the tumor-infiltrating immune cells of gliomas depending on COL5A1 and found that the percentages of the dendritic cells, which were known as the central mediator of tumor microenvironment in gliomas, were positively associated with the expression levels of COL5A1. Taken together, COL5A1 is an important biomarker and potential therapeutic target of gliomas.
format	article
author	Sujie Gu Zesheng Peng Zesheng Peng Yuxi Wu Yihao Wang Deqiang Lei Xiaobing Jiang Hongyang Zhao Peng Fu
author_facet	Sujie Gu Zesheng Peng Zesheng Peng Yuxi Wu Yihao Wang Deqiang Lei Xiaobing Jiang Hongyang Zhao Peng Fu
author_sort	Sujie Gu
title	COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas
title_short	COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas
title_full	COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas
title_fullStr	COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas
title_full_unstemmed	COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas
title_sort	col5a1 serves as a biomarker of tumor progression and poor prognosis and may be a potential therapeutic target in gliomas
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/0cdfcbe515de420083fb0eb4c747a0da
work_keys_str_mv	AT sujiegu col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas AT zeshengpeng col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas AT zeshengpeng col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas AT yuxiwu col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas AT yihaowang col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas AT deqianglei col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas AT xiaobingjiang col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas AT hongyangzhao col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas AT pengfu col5a1servesasabiomarkeroftumorprogressionandpoorprognosisandmaybeapotentialtherapeutictargetingliomas
_version_	1718426647441440768

COL5A1 Serves as a Biomarker of Tumor Progression and Poor Prognosis and May Be a Potential Therapeutic Target in Gliomas

Ejemplares similares